Shockwave Medical, Inc. (SWAV)

327.52 +0.02 (+0.01%) At close: 04:00PM EDT

Shockwave Medical, Inc.

5403 Betsy Ross Drive
Santa Clara, CA 95054
United States
510 279 4262
https://shockwavemedical.com

Sector(s): Healthcare
Industry: Medical Devices
Full-time employees: 1,468

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Douglas E. Godshall M.B.A.	President, CEO & Director	1.57M	20.1M	1965
Mr. Isaac Zacharias	Chief Commercial Officer	908.02k	4.76M	1975
Mr. Daniel Hawkins	Founder and Senior Advisor	N/A	N/A	1967
Mr. John M. Adams	Co-Founder and Technical Advisor	N/A	N/A	1947
Ms. Renee M. Gaeta	Chief Financial Officer	N/A	N/A	1982
Mr. Luis Morales	Senior Vice President of Global Operations	N/A	N/A	N/A
Ms. Trinh Phung	Chief Accounting Officer, Principal Accounting Officer & VP of Finance	N/A	N/A	1978
Ms. Debbie Kaster	Vice President of Investor Relations	N/A	N/A	N/A
Mr. Hajime Tada J.D.	General Counsel & Secretary	N/A	N/A	N/A
Mr. Robert Fletcher	Senior Vice President of Marketing & Market Access	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Shockwave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels. It also provides product for the treatment of coronary artery disease, such as C2 IVL catheter and C2+IVL catheter that are two-emitter catheters for use in IVL system; and Reducer, a device to treat refractory angina. In addition, the company develops COSIRA-II trial; shockwave C2 Aero, a coronary IVL catheter; shockwave javelin coronary, a non-balloon-based catheter platform to treat of tight, difficult-to-cross coronary lesions; shockwave L6; shockwave E8 catheter, to target long peripheral artery lesions; shockwave javelin peripheral, a non-balloon-based catheter platform, to treat tight, difficult-to-cross peripheral lesions. Further, it offers shockwave carotid IVL, a purpose-built IVL System to treat calcified carotid artery lesions; and Shockwave Crescendo, a platform developed to treat calcified, stenotic heart valves. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California.

Corporate governance

Shockwave Medical, Inc.’s ISS governance QualityScore as of 1 April 2024 is 6. The pillar scores are Audit: 5; Board: 5; Shareholder rights: 8; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.